Apogrez SA
Apogrez reported total assets of €1.37m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 Aug 2026).
The score of Apogrez shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -31 % Total assets -6 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apogrez's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 Aug 2026
- Year ended 31 Dec 2024filed on 28 Sep 2025
- Year ended 31 Dec 2023filed on 15 Oct 2024
- Year ended 31 Dec 2022filed on 25 Dec 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Apogrez's financial analysis
- Solvency38.1%sector median: 40.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apogrez
Apogrez's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0435.727.364
- VAT number
- BE0435727364
- Peppol
- Registered · 0208:0435727364 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 17 Nov 1988
- Registered office
- 1390 Grez-Doiceau
- Latest accounts
- 2025 · filed on 22 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apogrez (SA) has been based in Grez-Doiceau since 1988, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 8,830 € and equity of 520,779 €; its revenue is not published. Its solvency stands at 38.1%, below the median of its sector (40.1%).
Companies similar to Apogrez
Companies in the same business, of comparable size and area, outside its group.
- DE Spiegeleere - Discart Retail sale of pharmaceutical products Braine-l'Alleud · balance sheet €1.36m
- Decopharma Retail sale of pharmaceutical products Sint-Niklaas · balance sheet €1.36m
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Mast & CO Retail sale of pharmaceutical products Merchtem · balance sheet €1.36m
- AD Pharma Retail sale of pharmaceutical products Châtelet · balance sheet €1.37m
- Geerts Farma Retail sale of pharmaceutical products Vilvoorde · balance sheet €1.38m
- EVDW Retail sale of pharmaceutical products Ghent · balance sheet €1.38m
- Apotheek Zuiderkruis Retail sale of pharmaceutical products Antwerp · balance sheet €1.35m
Frequently asked questions about Apogrez
What is the revenue of Apogrez?
Apogrez files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apogrez?
In Belgium, the VAT number is the company number prefixed with BE: BE0435727364 for Apogrez, if the company is VAT-registered. Its company number (CBE) is 0435.727.364.
Where is the registered office of Apogrez?
According to the CBE register, the registered office of Apogrez is in 1390 Grez-Doiceau.
What is the equity of Apogrez?
At the close of the 2025 financial year, the equity of Apogrez amounts to 520,779 €, a solvency of 38.1% of total assets.
Who manages Apogrez?
The register lists 5 active mandates at Apogrez. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apogrez
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →